Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors.

Autor: Janka EA; Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.; HUN-REN-UD Allergology Research Group, University of Debrecen, 4032 Debrecen, Hungary., Szabó IL; Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.; HUN-REN-UD Allergology Research Group, University of Debrecen, 4032 Debrecen, Hungary., Kollár S; Institute of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.; Doctoral School of Health Sciences, University of Debrecen, 4032 Debrecen, Hungary., Toka-Farkas T; Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary., Ványai B; Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary., Várvölgyi T; Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary., Kapitány A; Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.; HUN-REN-UD Allergology Research Group, University of Debrecen, 4032 Debrecen, Hungary., Shabu H; Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary., Szegedi A; Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.; HUN-REN-UD Allergology Research Group, University of Debrecen, 4032 Debrecen, Hungary., Emri G; Department of Dermatology, MTA Centre of Excellence, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.; HUN-REN-UD Allergology Research Group, University of Debrecen, 4032 Debrecen, Hungary.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2024 Aug 27; Vol. 16 (17). Date of Electronic Publication: 2024 Aug 27.
DOI: 10.3390/cancers16172981
Abstrakt: Prognostic studies can provide important information about disease biology and improve the use of biomarkers to optimize treatment decisions.
Methods: A total of 199 patients with advanced melanoma treated with BRAF + MEK inhibitors were included in our single-center retrospective study. We analyzed the risk of progression and death using multivariate Cox proportional hazard models. The predictive effect of prognostic factors on progression-free survival (PFS) was evaluated in ROC analysis.
Results: We found that primary tumor localization, Clark level, pT category, baseline M stage and baseline serum S100B are independent and significant prognostic factors for PFS. The discriminative power of the combination of these factors was excellent for predicting 18 month PFS (AUC 0.822 [95% CI 0.727; 0.916], p < 0.001). Primary tumor localization on the extremities, Clark level V, baseline M1c stage or M1d stage, and elevated baseline serum S100B and LDH levels were independently and significantly associated with unfavorable overall survival (OS).
Conclusion: Baseline M stage and serum S100B appear to be independent prognostic factors for both PFS and OS in melanoma patients treated with BRAF + MEK inhibitors. We newly identified significant and independent prognostic effects of primary tumor localization and Clark level on survival that warrant further investigation.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje